The departments of Health and Human Services and Defense have agreed to purchase the first 300,000 doses of the investigational antibody drug bamlanivimab, also known as LY-CoV555, which state and territorial health departments will distribute to health care facilities for use in COVID-19 outpatients if the Food and Drug Administration authorizes the drug.

Under the $375 million agreement with drug maker Eli Lilly and Company, the federal government also can purchase up to 650,000 additional doses of the intravenous infusion drug, which is currently in phase 3 clinical trials.

Related News Articles

Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…